Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - tablet - see ingredients - each tablet contains carteolol hydrochloride 5 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - drops - see ingredients - each 5 ml solution contains carteolol hydrochloride 100 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

the premier pharmaceutical co ltd - drops - each 5 ml solution contains carteolol hydrochloride 50 mg

Israel - inglés - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.3 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - inglés - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.6 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Israel - inglés - Ministry of Health

medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.9 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Singapur - inglés - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 0.37621mg eqv. pasireotide - injection, solution - 0.3mg - pasireotide diaspartate 0.37621mg eqv. pasireotide 0.3mg

Singapur - inglés - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 0.75242mg eqv. pasireotide - injection, solution - 0.6 mg - pasireotide diaspartate 0.75242mg eqv. pasireotide 0.6 mg

Singapur - inglés - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 1.12863mg eqv. pasireotide - injection, solution - 0.9 mg - pasireotide diaspartate 1.12863mg eqv. pasireotide 0.9 mg

Unión Europea - inglés - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - pituitary and hypothalamic hormones and analogues - signifor is indicated for the treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.